Clinical Trials Directory

Trials / Completed

CompletedNCT05296759

Botulinum Toxin Type A in Diabetic Peripheral Neuropathy

A Comparative Study Of Botulinum Toxin Type A Versus Conventional Oral Therapy As A Second Line Treatment Of Diabetic Neuropathy

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Alexandria University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Background: Diabetes mellitus is commonly complicated by diabetic peripheral neuropathy. Due to common side effects and poor tolerance to medication, poor adherence to medication is common in diabetic peripheral neuropathy. Botulinum toxin A intradermal injection has proved efficacy in cases of diabetic peripheral neuropathy however there is a need to compare its effect with other lines of treatment. The aim of the study was to compare botulinum toxin type a verses conventional oral treatment as a second line treatment of painful diabetic peripheral neuropathy. This study was conducted as a comparative study on 30 patients with type 2 diabetes mellitus proved by nerve conduction study on carbamazepine. Patients were divided randomly into 3 groups. First group was add on duloxetine, second was add on gabapentin and the third group was injected intradermal with botulinum toxin A.

Detailed description

This study is a comparative study on 30 patients with type 2 diabetes mellitus proved by nerve conduction study on carbamazepine. Patients were divided randomly into 3 groups. First group was add on duloxetine, second was add on gabapentin and the third group was injected intradermal with Botulinum toxin A. Base line Assessment before treatment and follow up assessment as performed The treatment options were explained to the patients and the choice of Botulinum toxin A Intradermal injection was the patient own decision based on inability to be tolerate or adhere to oral treatment.

Conditions

Interventions

TypeNameDescription
DRUGbotulinum toxin Abotulinum toxin A injection
DRUGGabapentinGabapentin oral intake
DRUGDuloxetineDuloxetine oral drug intake

Timeline

Start date
2021-02-01
Primary completion
2021-11-01
Completion
2022-03-08
First posted
2022-03-25
Last updated
2022-04-06

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05296759. Inclusion in this directory is not an endorsement.